Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 12/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 6/20 | 0.48 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987072 | 1.00 | TGM2 (0.52) | TGM2CTSLHDAC1HDAC2CTSB | |
| SCHEMBL2861817 | 0.95 | TGM2 (0.55) | TGM2CTSLHDAC1HDAC2CTSB | |
| SCHEMBL2861823 | 0.95 | TGM2 (0.55) | TGM2CTSLHDAC1HDAC2CTSB | |
| SCHEMBL11100666 | 0.80 | TGM2 (0.60) | TGM2CTSLHDAC1HDAC2CTSB | |
| SCHEMBL8713258 | 0.79 | CTSL (0.65) | TGM2CTSLCTSBITGB3 | |
| SCHEMBL951558 | 0.79 | CTSL (0.65) | TGM2CTSLCTSBITGB3 | |
| SCHEMBL11144067 | 0.79 | CTSL (0.65) | TGM2CTSLCTSBITGB3 | |
| SCHEMBL11138908 | 0.79 | CTSL (0.65) | TGM2CTSLCTSBITGB3 | |
| SCHEMBL2487005 | 0.78 | CTSL (0.65) | CTSLCTSB | |
| SCHEMBL1796250 | 0.78 | CTSL (0.65) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268469-B1 | N-(HETEROCYCLYL)BENZENE OR PYRIDINE SULPHONAMIDES AS ANTITHROMBOTIC AGENTS AND ANTICOAGULANTS | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6680329-B2 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-SYNTHELABO (FR) | 2004-01-20 | — | — | US | disclosed |
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-AVENTIS (FR) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | PROC, VKORC1, SERPINC1 | TGM2 4295/4885CTSL 498/4885HDAC1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.